Patents by Inventor Philip R. Dormitzer

Philip R. Dormitzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240034773
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: May 24, 2023
    Publication date: February 1, 2024
    Inventors: Kurt SWANSON, Philip R. DORMITZER
  • Patent number: 11827694
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: November 28, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt Swanson, Philip R. Dormitzer
  • Patent number: 11820812
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: November 21, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt Swanson, Philip R. Dormitzer
  • Publication number: 20230357371
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: May 24, 2023
    Publication date: November 9, 2023
    Inventors: Kurt SWANSON, Philip R. DORMITZER
  • Publication number: 20230357369
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: May 24, 2023
    Publication date: November 9, 2023
    Inventors: Kurt SWANSON, Philip R. DORMITZER
  • Publication number: 20230357370
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: May 24, 2023
    Publication date: November 9, 2023
    Inventors: Kurt SWANSON, Philip R. DORMITZER
  • Publication number: 20230348575
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: May 24, 2023
    Publication date: November 2, 2023
    Inventors: Kurt SWANSON, Philip R. DORMITZER
  • Publication number: 20230348574
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: February 22, 2023
    Publication date: November 2, 2023
    Inventors: Kurt SWANSON, Philip R. DORMITZER
  • Publication number: 20230303669
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: May 24, 2023
    Publication date: September 28, 2023
    Inventors: Kurt SWANSON, Philip R. DORMITZER
  • Patent number: 11655284
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: May 23, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt Swanson, Philip R. Dormitzer
  • Patent number: 11629181
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: April 18, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt Swanson, Philip R. Dormitzer
  • Publication number: 20220372115
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: June 23, 2022
    Publication date: November 24, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt SWANSON, Philip R. DORMITZER
  • Publication number: 20220340645
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 27, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt SWANSON, Philip R. DORMITZER
  • Publication number: 20220213177
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: December 29, 2021
    Publication date: July 7, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt SWANSON, Philip R. DORMITZER
  • Patent number: 11261239
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: March 1, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt Swanson, Philip R. Dormitzer
  • Publication number: 20200172600
    Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
    Type: Application
    Filed: August 16, 2017
    Publication date: June 4, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Kurt Swanson, Philip R. Dormitzer
  • Patent number: 10287324
    Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 14, 2019
    Assignee: NOVARTIS AG
    Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
  • Patent number: 10192025
    Abstract: The present invention relates to the use of rotavirus particles for displaying a heterologous protein, alone or in complex with another molecule. The invention further relates to methods that employ these modified rotavirus particles to rapidly determine the structure of the heterologous protein or the complex using cryo-electron microscopy (cryo-EM). The invention also relates to a method of immunizing a patient, wherein said method comprises administering to the patient the modified rotavirus particles of the invention.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: January 29, 2019
    Assignee: Novartis AG
    Inventors: Philip R. Dormitzer, Nikolaus Grigorieff, Stephen Harrison, Junhua Pan, Ethan Settembre
  • Publication number: 20190023746
    Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain.
    Type: Application
    Filed: August 2, 2018
    Publication date: January 24, 2019
    Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
  • Patent number: 10065994
    Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: September 4, 2018
    Assignee: Novartis AG
    Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer